S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:AERIAerie Pharmaceuticals Stock Price, Forecast & News

$12.71
+0.33 (+2.67 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.24
Now: $12.71
$12.87
50-Day Range
$11.56
MA: $13.21
$15.79
52-Week Range
$10.80
Now: $12.71
$26.26
Volume453,586 shs
Average Volume916,018 shs
Market Capitalization$591.19 million
P/E RatioN/A
Dividend YieldN/A
Beta0.94
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Read More
Aerie Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AERI
CUSIPN/A
Phone919-237-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$69.89 million
Book Value$1.93 per share

Profitability

Net Income$-199,580,000.00
Net Margins-247.36%

Miscellaneous

Employees353
Market Cap$591.19 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$12.71
+0.33 (+2.67 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for AERI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

How has Aerie Pharmaceuticals' stock been impacted by Coronavirus?

Aerie Pharmaceuticals' stock was trading at $14.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AERI stock has decreased by 12.6% and is now trading at $12.71.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Aerie Pharmaceuticals?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aerie Pharmaceuticals
.

When is Aerie Pharmaceuticals' next earnings date?

Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Aerie Pharmaceuticals
.

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals Inc (NASDAQ:AERI) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.79) by $0.04. Aerie Pharmaceuticals had a negative return on equity of 107.42% and a negative net margin of 247.36%.
View Aerie Pharmaceuticals' earnings history
.

What price target have analysts set for AERI?

13 Wall Street analysts have issued 1-year price objectives for Aerie Pharmaceuticals' stock. Their forecasts range from $17.00 to $50.00. On average, they expect Aerie Pharmaceuticals' stock price to reach $30.08 in the next year. This suggests a possible upside of 136.7% from the stock's current price.
View analysts' price targets for Aerie Pharmaceuticals
.

Has Aerie Pharmaceuticals been receiving favorable news coverage?

News headlines about AERI stock have trended somewhat negative on Friday, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aerie Pharmaceuticals earned a coverage optimism score of -1.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Aerie Pharmaceuticals
.

Are investors shorting Aerie Pharmaceuticals?

Aerie Pharmaceuticals saw a decline in short interest in the month of July. As of July 31st, there was short interest totaling 8,050,000 shares, a decline of 10.6% from the July 15th total of 9,000,000 shares. Based on an average daily trading volume, of 879,200 shares, the short-interest ratio is currently 9.2 days. Approximately 18.4% of the shares of the stock are short sold.
View Aerie Pharmaceuticals' Short Interest
.

Who are some of Aerie Pharmaceuticals' key competitors?

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Canopy Growth (CGC), NicOx (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), NVIDIA (NVDA), Puma Biotechnology (PBYI), Wells Fargo & Co (WFC), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD) and Incyte (INCY).

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the following people:
  • Dr. Vicente J. Anido Jr., CEO & Chairman (Age 66)
  • Mr. Thomas A. Mitro, Pres & COO (Age 61)
  • Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 58)
  • Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 61)
  • Ms. Jessica Crespo CPA, Director of Accounting

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Who are Aerie Pharmaceuticals' major shareholders?

Aerie Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.16%), Bank of America Corp DE (4.78%), William Blair Investment Management LLC (2.95%), Bank of New York Mellon Corp (2.76%), Point72 Asset Management L.P. (1.83%) and Candriam Luxembourg S.C.A. (1.27%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr.
View institutional ownership trends for Aerie Pharmaceuticals
.

Which major investors are selling Aerie Pharmaceuticals stock?

AERI stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, SG Americas Securities LLC, FMR LLC, Rhenman & Partners Asset Management AB, Vanguard Group Inc., Candriam Luxembourg S.C.A., Bank of New York Mellon Corp, and CWM LLC.
View insider buying and selling activity for Aerie Pharmaceuticals
.

Which major investors are buying Aerie Pharmaceuticals stock?

AERI stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Bank of America Corp DE, Point72 Asset Management L.P., Goldman Sachs Group Inc., Granite Investment Partners LLC, Barclays PLC, Frontier Capital Management Co. LLC, and Cubist Systematic Strategies LLC. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino, and Vicente Anido Jr.
View insider buying and selling activity for Aerie Pharmaceuticals
.

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $12.71.

How big of a company is Aerie Pharmaceuticals?

Aerie Pharmaceuticals has a market capitalization of $591.19 million and generates $69.89 million in revenue each year. The company earns $-199,580,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Aerie Pharmaceuticals employs 353 workers across the globe.

What is Aerie Pharmaceuticals' official website?

The official website for Aerie Pharmaceuticals is www.aeriepharma.com.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.